Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn:
“New Must-Read Commentary in The Oncologist Journal
Why RECIST v1.1 is a flawed metric for real-world evidence (RWE) in oncology retrospective studies.
The article argues that attempting to apply rigid clinical trial criteria to real-world data is often misleading due to inconsistent imaging intervals, modalities, and radiology reporting.
Instead, the authors make a compelling case for using endpoints like Time to Treatment Discontinuation (TTD) and Time to Next Treatment (TTNT), which often more accurately reflect clinical decisions and true disease progression in a real-world setting.
This is essential reading for anyone in oncology drug development, real-world evidence generation, or health outcomes research.”
More insights from Giuseppe Banna.